文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

开具者对联苯基硫代嘌呤S-甲基转移酶检测药物基因组学临床决策支持的响应评价

Evaluation of prescriber responses to pharmacogenomics clinical decision support for thiopurine S-methyltransferase testing.
PubMed 文献 · Am J Health Syst Pharm · 2018-01-01

该单中心回顾性病历审查研究评估了开具者对提示检测TPMT状态的药物基因组学CDS弹窗的依从性。9个月内生成500条警报,仅20%(101例)开具了TPMT表型或基因型检测,80%(399例)未开具。历史硫代嘌呤使用记录是唯一独立预测检测开具的因素。在线剂量资源使用率低,仅3例按指南支持剂量处方。

要点

  • TPMT预检CDS警报的检测开具率仅20%(101/500),提示警报疲劳与准确性不足。
  • 历史硫代嘌呤使用记录是检测开具的唯一独立预测因素。
  • 99例受检患者中71%活性正常、29%中间、无缺乏;在线剂量资源仅3例被遵循使用。

核心结论

  • 预检CDS规则因警报准确性差导致大部分警报被忽略并引发警报疲劳。
  • 开具者对在线硫代嘌呤剂量资源的使用率低。

研究设计与样本

  • 单中心、回顾性、基于病历审查的研究。
  • 研究评估开具者对预检CDS警报的依从性,该警报提示TPMT基因多态性所致TPMT活性缺乏可能引起硫代嘌呤药物毒性。
  • 警报触发条件为开具硫代嘌呤药物时患者记录未显示TPMT状态或电子健康记录中有历史硫代嘌呤使用记录。
  • 研究周期9个月,共生成500条CDS警报。

主要发现

  • 101例(20%)开具了TPMT表型或TPMT基因型检测,399例(80%)未开具检测。
  • 多变量回归分析显示,历史硫代嘌呤使用记录是检测开具的唯一独立预测因素。
  • CDS警报后接受检测的99例患者中,70例(71%)TPMT活性正常,29例(29%)活性中间,无活性缺乏者。
  • 在线资源提供的硫代嘌呤剂量推荐适用于24例患者,但仅3例在CDS警报后按指南支持剂量处方。

临床怎么用

  • 临床药师应关注TPMT预检CDS警报的准确性,减少无效警报以降低警报疲劳。
  • 对存在历史硫代嘌呤使用记录的患者,可优先强化TPMT检测提示。
  • 需主动推动开具者使用在线硫代嘌呤剂量计算资源,促进指南支持剂量落地。

局限性

  • 单中心、回顾性、基于病历审查的设计可能限制结果外推。
  • 研究未报告警报准确性具体评估指标及混杂因素控制细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Results of a study of prescribers' responses to a pharmacogenomics-based clinical decision support (CDS) alert designed to prompt thiopurine S-methyltransferase (TPMT) status testing are reported. METHODS: A single-center, retrospective, chart review-based study was conducted to evaluate prescriber compliance with a pretest CDS alert that warned of potential thiopurine drug toxicity resulting from deficient TPMT activity due to TPMT gene polymorphism. The CDS alert was triggered when prescribers ordered thiopurine drugs for patients whose records did not indicate TPMT status or when historical thiopurine use was documented in the electronic health record. The alert pop-up also provided a link to online educational resources to guide thiopurine dosing calculations. RESULTS: During the 9-month study period, 500 CDS alerts were generated: in 101 cases (20%), TPMT phenotyping or TPMT genotyping was ordered; in 399 cases (80%), testing was not ordered. Multivariable regression analysis indicated that documentation of historical thiopurine use was the only independent predictor of test ordering. Among the 99 patients tested subsequent to CDS alerts, 70 (71%) had normal TPMT activity, 29 (29%) had intermediate activity, and none had deficient activity. The online resources provided thiopurine dosing recommendations applicable to 24 patients, but only 3 were prescribed guideline-supported doses after CDS alerts. CONCLUSION: The pretest CDS rule resulted in a large proportion of neglected alerts due to poor alerting accuracy and consequent alert fatigue. Prescriber usage of online thiopurine dosing resources was low.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Ubanyionwu S, Formea CM, Anderson B, et al. Evaluation of prescriber responses to pharmacogenomics clinical decision support for thiopurine S-methyltransferase testing. Am J Health Syst Pharm. 2018. PMID: 29436466. doi:10.2146/ajhp170280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。